Acta is trade terrorism
India’s generic medicines export faces a huge threat from the anti-counterfeiting law which creates barriers to global trade
Why do we need patents?
There is no empirical evidence that patents serve to increase innovation and productivity
Tesla's `insane' move to free up patents
The electric carmaker's decision could spur a revolution in green vehicles and in the way patents are viewed
Prometheus bound
The denial of a patent on a medical test that correlates drug dosages with treatment could mean the end of human gene patents
Affordable medicines row
The US pharmaceutical industry -- which has so far prevented its government from endorsing a prescription for change -- is now directly engaging …
FARM IP, ENTER WIPO
Developing countries will now have to battle IP issues related to new agricultural technologies at WIPO instead of WTO
Brickbats for compulsory licences
US criticises India and BRIC group for strengthening provisions on life-saving medicines
Japanese biopiracy of our Ballia barley
Japan’s Sapporo brewery patents Indian barley gene without giving benefit to farmers
Getting the drug equation right
Sonal Matharu reports how fights over counterfeit drugs and low-quality drugs is suppressing the larger issue of drug safety
Rotten tomato for Monsanto
US biotech giant's claim on a natural tomato is its latest patent to be revoked by Europe after soy and wheat
The fine line for judges
Judges have recused themselves in a number of cases but there are no clear guidelines on what constitutes conflict of interest
Maths of Gilead's hepatitis C drug
Why US firm's super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price
Cipla's bitter pill for MNCs
Several eyebrows have been raised over the Cipla offer to supply anti- aids drugs at one-third the current price to developing countries like …
Obama takes first dip
The US becomes the first to join a global patents pool to make AIDS drugs cheaper but health workers are sceptical of the initiative
Access, yes. Sharing, no
The access and benefit-sharing protocol on biodiversity may do little to deter multinationals from grabbing the planet’s resources
Evergreen Novartis
The Swiss pharma giant’s challenge to India’s patent law, now in the Supreme Court, may help define drug efficacy
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
Monsanto does it again
The biotech seed giant sues a farmer for planting unbranded commodity seeds bought in the open market for patent infringement
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
It’s still open season for bio-piracy
Rich nations block accord on benefit-sharing rules for the world’s genetic resources
Gunning for green tech
US continues to target India over its intellectual property regime, especially in pharma, green tech sectors
Crazy GM patent system
The Brazilian lawsuit against Monsanto’s royalty on soybean seeds exposes the irrational way in which laws apply to GM crops
Righting the copywrong
Amending the Copyright Act to give directors, composers and musicians rights over their work has corrected a historic wrong but trouble is brewing
Choking access to drugs
Drug prices are likely to increase as rich countries and their pharma companies squeeze Indian generics out of the market. How can India’s …
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards